Transaction #38190 · Form 4 · 0001681643-26-000008
REGENERON PHARMACEUTICALS, INC. · Exercise / conversion · Common Stock
REGENERON PHARMACEUTICALS, INC. · Transacted November 3, 2026 · Filed November 5, 2026
What does this filing report?
An SEC Form 4 filing for REGENERON PHARMACEUTICALS, INC. records an exercise / conversion involving Common Stock on November 3, 2026. The reported quantity was 7,439. The filing date is November 5, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0000872589
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 7,439
- Reported price
- 380.95
- Reference value
- 2,833,887.05
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 9,142
- Ownership description
- Not reported
- SEC acceptance time
- Nov 5, 2026, 4:05 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Zoghbi Huda Y ↗
Director
CIK 0001681643
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Represents volume-weighted average price of sales of 6,939 shares of Company stock on November 3, 2026 at prices ranging from $970.00 to $970.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 3, 2026 at each separate price.
- F2
- Represents volume-weighted average price of sales of 500 shares of Company stock on November 3, 2026 at prices ranging from $971.00 to $971.11. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 3, 2026 at each separate price.
- F3
- The stock option vested in three equal annual installments, commencing one year after the date of grant.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.